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Niemann-Pick disease type C (NPC) is a rare autosomal recessive, lysosomal 
storage disease characterized by impaired intracellular lipid trafficking leading 
to accumulation of cholesterol and glycosphingolipids in various tissues. NP-C 
is characterized by visceral, neurological, and psychiatric manifestation.
Until recently, there was no curative treatment for NP-C; management remains 
mainly supportive and symptomatic treatment to improve health-related quality 
of life (HRQOL). Now the disease-specific treatment approved. The aims of the 
treatment are to stabilize or slow disease progression.
 Miglustat (N-butyldeoxynojirimycin; NB- DNJ; Zavesca) is the only disease-
specific oral therapy approved to treat progressive neurological manifestation 
of NP-C. Iminosugar molecule reversibly inhibits glycosphingolipid synthesis. 
It has beneficial effects on lipid trafficking defects, reducing the neurotoxic 
accumulation of glucosylceramide, lactosylceramide, and gangliosides GM2 
and GM3 in the brain and delaying the progression of neurological symptoms 
of NP-C but it has no effect on the systemic manifestations.
NBDNJ appears to have pleotropic effects in humans, as demonstrated by its 
ability to reduce GSL accumulation and inflammation. Nevertheless, it has the 
potential adverse molecular effects on cellular processes, including signalling 
protein localization. It causes reduced conduction velocity and myelination, 
axonal degeneration, and increases susceptibility to excitotoxicity. Ganglioside 
reduction and substrate deprivation by NBDNJ treatment is a more viable 
treatment in humans because the drug does not result in permanent depletion of 
the ganglioside reserves.
 Miglustat should be started immediately at the earliest sign of neurological 
manifestation. The recommended dose of miglustat for the treatment of patients 
12 years of age and above is
200mg three times a day and dosing in patients under the age of 12 years should 
be adjusted based on body surface area. The most common adverse effects 
associated with miglustat treatment are gastrointestinal with mild to moderate 
diarrhea, vomiting, flatulence, and weight loss tending to decrease over time.
For patients whose diagnosis is based on sibling screening or systemic 
manifestation of NP-C with initiation of miglustat at the first neurological 
sign, the response is generally better. There is very limited data of effective of 
treatment with miglustat to prevent neurological symptoms for asymptomatic 
patients.
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